Nothing Special   »   [go: up one dir, main page]

AU2495200A - Compositions and methods for the treatment of tumor - Google Patents

Compositions and methods for the treatment of tumor

Info

Publication number
AU2495200A
AU2495200A AU24952/00A AU2495200A AU2495200A AU 2495200 A AU2495200 A AU 2495200A AU 24952/00 A AU24952/00 A AU 24952/00A AU 2495200 A AU2495200 A AU 2495200A AU 2495200 A AU2495200 A AU 2495200A
Authority
AU
Australia
Prior art keywords
tumor
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24952/00A
Inventor
Avi J. Ashkenazi
Kevin P. Baker
Audrey Goddard
Austin L. Gurney
Kenneth J. Hillan
Margaret Ann Roy
Colin K. Watanabe
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/en
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/en
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/en
Priority claimed from PCT/US1999/030911 external-priority patent/WO2000075316A1/en
Priority claimed from PCT/US2000/000219 external-priority patent/WO2000053753A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2495200A publication Critical patent/AU2495200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU24952/00A 1999-03-08 2000-01-06 Compositions and methods for the treatment of tumor Abandoned AU2495200A (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
WOUS9905028 1999-03-08
PCT/US1999/005028 WO1999046281A2 (en) 1998-03-10 1999-03-08 Novel polypeptides and nucleic acids encoding the same
PCT/US1999/012252 WO1999063088A2 (en) 1998-06-02 1999-06-02 Membrane-bound proteins and nucleic acids encoding the same
WOUS9912252 1999-06-02
US14103799P 1999-06-23 1999-06-23
US60141037 1999-06-23
US14304899P 1999-07-07 1999-07-07
US60143048 1999-07-07
US14569899P 1999-07-26 1999-07-26
US60145698 1999-07-26
WOUS9928313 1999-11-30
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US1999/030911 WO2000075316A1 (en) 1999-06-02 1999-12-20 Methods and compositions for inhibiting neoplastic cell growth
WOUS9930911 1999-12-20
PCT/US2000/000219 WO2000053753A2 (en) 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization
WOUS0000219 2000-01-05
PCT/US2000/000376 WO2000053755A2 (en) 1999-03-08 2000-01-06 Compositions and methods for the treatment of tumor

Publications (1)

Publication Number Publication Date
AU2495200A true AU2495200A (en) 2000-09-28

Family

ID=56289989

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24952/00A Abandoned AU2495200A (en) 1999-03-08 2000-01-06 Compositions and methods for the treatment of tumor

Country Status (2)

Country Link
AU (1) AU2495200A (en)
WO (1) WO2000053755A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001248840B2 (en) * 2000-04-21 2005-06-09 Fuso Pharmaceutical Industries, Ltd. Novel collectins

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
KR20000070174A (en) 1997-01-14 2000-11-25 벤슨 로버트 에이치. Tumor necrosis factor receptors 6α and 6β
US7053190B2 (en) 1997-03-07 2006-05-30 Human Genome Sciences, Inc. Secreted protein HRGDF73
US6242419B1 (en) * 1999-03-25 2001-06-05 Genesis Research & Development Corporation Ltd. Compositions isolated from stromal cells and methods for their use
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU1915201A (en) * 1999-12-07 2001-06-18 Eli Lilly And Company Improving stability of flint through o-linked glycosylation
JP4280444B2 (en) * 2000-01-06 2009-06-17 ジェネンテック・インコーポレーテッド Compositions and methods for inhibiting neoplastic cell growth
GB0004576D0 (en) * 2000-02-25 2000-04-19 Oxford Glycosciences Uk Ltd Proteins
US20040141974A1 (en) * 2000-02-25 2004-07-22 Boyd Robert Simon Diagnostic and therapeutic methods
EP1666594A3 (en) * 2000-06-02 2006-06-21 Genentech, Inc. Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
JP2004520354A (en) * 2000-11-22 2004-07-08 イミュネックス・コーポレーション Uses of IMXP-888 and IMXP-888 antagonists
ES2365023T3 (en) 2004-04-21 2011-09-20 Enobia Pharma Inc. CONJUGATES OF BONE ADMINISTRATION AND METHOD OF USE OF THE SAME TO DIRECT BONE PROTEINS.
ES2633453T3 (en) 2008-01-24 2017-09-21 Esperance Pharmaceuticals Constructs of fusion of lithic domains and methods of preparation and use thereof
EP2213686A1 (en) * 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
DK2914633T3 (en) 2012-10-30 2022-03-14 Esperance Pharmaceuticals Inc ANTIBODY / MEDICINAL CONJUGATES AND METHODS OF USE
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
KR20240045379A (en) 2014-12-05 2024-04-05 알렉시온 파마슈티칼스, 인코포레이티드 Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
MX2018002121A (en) 2015-08-17 2018-06-18 Alexion Pharma Inc Manufacturing of alkaline phosphatases.
JP6868617B2 (en) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド Identifying effective dosing regimens for tissue-nonspecific alkaline phosphatase (TNSALP) enzyme replacement therapy for hypophosphataseemia
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20220162816A (en) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 Treating muscle weakness with alkaline phosphatases
CA3021644A1 (en) * 2016-05-06 2017-11-09 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
JP2020512363A (en) 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods for treating hypophosphatasia (HPP) in adults and adolescents
JP2021519590A (en) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド Glycoprotein production
CN117042791A (en) 2021-02-12 2023-11-10 阿雷克森制药公司 Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000603A1 (en) * 1992-06-26 1994-01-06 The Trustees Of Princeton University Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
KR20000070174A (en) * 1997-01-14 2000-11-25 벤슨 로버트 에이치. Tumor necrosis factor receptors 6α and 6β
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
WO1999004001A1 (en) * 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
DE69839401T2 (en) * 1997-09-18 2009-05-07 Genentech Inc., San Francisco DCR3 POLYPEPTIDE, A TNFR HOMOLOG

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001248840B2 (en) * 2000-04-21 2005-06-09 Fuso Pharmaceutical Industries, Ltd. Novel collectins

Also Published As

Publication number Publication date
WO2000053755A2 (en) 2000-09-14
WO2000053755A3 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2212299A (en) Compositions and methods for the treatment of tumor
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU6147401A (en) Compositions and methods for the treatment of cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
IL141426A0 (en) Compositions and methods for the treatment of tumor
IL143212A0 (en) Compositions and methods for the treatment of tumor
AU1878201A (en) Composition for the treatment of damaged tissue
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2001296224A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2566201A (en) Compounds and methods for the treatment of pain
AUPQ367699A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
AU2420101A (en) Method and composition for the treatment of pain
AU4452900A (en) Compositions and methods for the therapy and diagnosis of prostate cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase